Prevalence and Treatment of Substance Misuse in Older Adults: Beyond Early Adulthood

References

• Spencer M, Curtin S, Garnett M. Alcohol-induced death rates in the United States, 2019–2020. NCHS. 2022; 448. doi:10.15620/cdc:121795
   Google Scholar
• State Medical Cannabis Laws. www.ncsl.org. Available from: http://www.ncsl.org/health/state-medical-cannabis-laws#:~:text=Medical%2DUse%20Update. Accessed July 4, 2024.
   Google Scholar
• Wolfe D, Corace K, Butler C, et al. Impacts of medical and non-medical cannabis on the health of older adults: findings from a scoping review of the literature. PLoS One. 2023;18(2):e0281826. doi:10.1371/journal.pone.0281826
   PubMed Web of Science ®Google Scholar
• Shoff C, Yang TC, Shaw BA. Trends in opioid use disorder among older adults: analyzing medicare data, 2013-2018. Am J Prev Med. 2021;60(6):850–855. doi:10.1016/j.amepre.2021.01.010
   PubMed Web of Science ®Google Scholar
• Substance Abuse And Mental Health Service Administration (SAMHSA). National survey on drug use and health (NSDUH) detailed tables | CBHSQ data. 2020; Available from: https://www.samhsa.gov/data/report/2020-nsduh-detailed-tables. Accessed January 11, 2022.
   Google Scholar
• Grucza RA, Sher KJ, Kerr WC, et al. Trends in adult alcohol use and binge drinking. Alcoho, Clini Exp Res. 2018;42(10):1939–1950. doi:10.1111/acer.13859
   PubMed Web of Science ®Google Scholar
• Gfroerer J, Penne M, Pemberton M, Folsom R. Substance abuse treatment need among older adults in 2020: the impact of the aging baby-boom cohort. Drug Alcohol Depend. 2003;69(2):127–135. doi:10.1016/s0376-8716(02)00307-1
   PubMed Web of Science ®Google Scholar
• Grant BF, Chou SP, Saha TD, et al. Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001-2002 to 2012-2013: results from the national epidemiologic survey on alcohol and related conditions. JAMA Psychiatry. 2017;74(9):911–923. doi:10.1001/jamapsychiatry.2017.2161
   PubMed Web of Science ®Google Scholar
• National Institute on Alcohol Abuse and Alcoholism. Drinking levels defined. Nih.gov. 2023; Available from: https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/moderate-binge-drinking. Accessed 2024.
   Google Scholar
• Older adults | national institute on alcohol abuse and alcoholism (NIAAA). www.niaaa.nih.gov. https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-topics/older-adults#:~:text=The%20size%20of%20the%20older. Accessed july 9, 2024.
   Google Scholar
• Nuevo R, Chatterji S, Verdes E, Naidoo N, Ayuso-Mateos JL, Miret M. Prevalence of alcohol consumption and pattern of use among the elderly in the WHO European region. Eur Addict Res. 2015;21(2):88–96. doi:10.1159/000360002
   PubMed Web of Science ®Google Scholar
• Ahlner F, Falk Erhag H, Johansson L, et al. Patterns of alcohol consumption and associated factors in a population-based sample of 70-year-olds: data from the Gothenburg H70 Birth Cohort Study 2014-16. Int J Environ Res Public Health. 2022;19(14):8248. doi:10.3390/ijerph19148248
   PubMed Web of Science ®Google Scholar
• Midorikawa H, Tachikawa H, Aiba M, Arai T, Watanabe T, Tamiya N. Factors associated with high-risk drinking in older adults: evidence from a national survey in Japan. Geriatr Gerontol Int. 2019;19(12):1260–1267. doi:10.1111/ggi.13808
   PubMed Web of Science ®Google Scholar
• Esser MB, Sherk A, Liu Y, et al. Deaths and years of potential life lost from excessive alcohol use - United States, 2011-2015 [published correction appears in MMWR Morb Mortal Wkly Rep. MMWR Morb Mortal Wkly Rep. 2020;69(30):981–987. doi:10.15585/mmwr.mm6930a1
   PubMed Web of Science ®Google Scholar
• Moore AA, Giuli L, Gould R, et al. Alcohol use, comorbidity, and mortality. J Am Geriatr Soc. 2006;54(5):757–762. doi:10.1111/j.1532-5415.2006.00728.x
   PubMed Web of Science ®Google Scholar
• Muvvala SB, O’Malley SS, Rosenheck R. Multiple psychiatric morbidity and continued use of naltrexone for alcohol use disorder. Am J Addict. 2021;30(1):55–64. doi:10.1111/ajad.13089
   PubMed Web of Science ®Google Scholar
• Oslin D, Liberto JG, O’Brien J, Krois S, Norbeck J. Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am J Geriatr Psychiatry. 1997;5(4):324–332. doi:10.1097/00019442-199700540-00007
   PubMed Web of Science ®Google Scholar
• Mason BJ, Heyser CJ. Alcohol use disorder: the role of medication in recovery. Alcohol Res. 2021;41(1):07. doi:10.35946/arcr.v41.1.07
   PubMed Web of Science ®Google Scholar
• Anton RF, O’Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003–2017. doi:10.1001/jama.295.17.2003
   PubMed Web of Science ®Google Scholar
• Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311(18):1889–1900. doi:10.1001/jama.2014.3628
   PubMed Web of Science ®Google Scholar
• Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and Acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013;108(2):275–293. doi:10.1111/j.1360-0443.2012.04054.x
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Morris PE, Pond T, et al. Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder. Neuropsychopharmacol. 2021;46(8):1407–1413. doi:10.1038/s41386-020-00945-9
   PubMed Web of Science ®Google Scholar
• Blodgett JC, Del Re AC, Maisel NC, Finney JW. A meta-analysis of topiramate’s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res. 2014;38(6):1481–1488. doi:10.1111/acer.12411
   PubMed Web of Science ®Google Scholar
• Ray LA, Meredith LR, Kiluk BD, Walthers J, Carroll KM, Magill M. Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders: a systematic review and meta-analysis. JAMA Network Open. 2020;3(6):e208279. doi:10.1001/jamanetworkopen.2020.82799
   PubMed Web of Science ®Google Scholar
• Kelly JF, Humphreys K, Ferri M. Alcoholics Anonymous and other 12-step programs for alcohol use disorder. Cochrane Database Syst Rev. 2020;3(3):CD012880. doi:10.1002/14651858.CD012880.pub2
   PubMedGoogle Scholar
• Han BH, Palamar JJ. Marijuana use by middle-aged and older adults in the United States, 2015-2016 [published correction appears in drug alcohol depend. Drug Alcohol Depend. 2018;191:374–381. doi:10.1016/j.drugalcdep.2018.07.006
   PubMed Web of Science ®Google Scholar
• Han BH, Sherman S, Mauro PM, Martins SS, Rotenberg J, Palamar JJ. Demographic trends among older cannabis users in the United States, 2006-13. Addiction. 2017;112(3):516–525. doi:10.1111/add.13670
   PubMed Web of Science ®Google Scholar
• Yang KH, Kaufmann CN, Nafsu R, et al. Cannabis: an emerging treatment for common symptoms in older adults. J Am Geriatr Soc. 2021;69(1):91–97. doi:10.1111/jgs.16833
   PubMed Web of Science ®Google Scholar
• Kaufmann CN, Malhotra A, Yang KH, et al. Cannabis use for sleep disturbance among older patients in a geriatrics clinic. Int J Aging Hum Dev. 2023;97(1):3–17. doi:10.1177/00914150221128971
   PubMed Web of Science ®Google Scholar
• Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry. 2015;72(12):1235–1242. doi:10.1001/jamapsychiatry.2015.1858
   PubMed Web of Science ®Google Scholar
• Rotermann M. What has changed since cannabis was legalized? Health Rep. 2020;31(2):11–20. doi:10.25318/82-003-x202000200002-eng
   PubMed Web of Science ®Google Scholar
• Government of Canada SC. The daily — national cannabis survey, third quarter 2019. www150.statcan.gc.ca. Available from: https://www150.statcan.gc.ca/n1/daily-quotidien/191030/dq191030a-eng.htm. Accessed October 30, 2019.
   Google Scholar
• Abuhasira R, Schleider LB, Mechoulam R, Novack V. Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. Eur J Intern Med. 2018;49:44–50. doi:10.1016/j.ejim.2018.01.019
   PubMed Web of Science ®Google Scholar
• Schleider L B-L, Mechoulam R, Lederman V, et al. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. Eur J Intern Med. 2018;49:37–43. doi:10.1016/j.ejim.2018.01.023
   PubMed Web of Science ®Google Scholar
• Substance Abuse Mental Health Services Administration (SAMHSA) MHS. Treatment Improvement Protocol (TIP) 26: treating substance use disorder in older adults. 2020; Available from: https://store.samhsa.gov/product/treatment-improvement-protocol-tip-26-treating-substance-use-disorder-in-older-adults/PEP20-02-01-011. Accessed july 9 2024.
   Google Scholar
• Bertram JR, Porath A, Seitz D, et al. Canadian guidelines on cannabis use disorder among older adults. Can Geriatr J. 2020;23(1):135–142. doi:10.5770/cgj.23.424
   PubMed Web of Science ®Google Scholar
• Kondo KK, Morasco BJ, Nugent SM, et al. Pharmacotherapy for the treatment of cannabis use disorder: a systematic review. Ann Intern Med. 2020;172(6):398–412. doi:10.7326/M19-1105
   PubMed Web of Science ®Google Scholar
• McRae-Clark AL, Carter RE, Killeen TK, et al. A placebo-controlled trial of buspirone for the treatment of marijuana dependence. Drug Alcohol Depend. 2009;105(1–2):132–138. doi:10.1016/j.drugalcdep.2009.06.022
   PubMed Web of Science ®Google Scholar
• McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, White KG, Brady KT. A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. Am J Addict. 2010;19(6):481–489. doi:10.1111/j.1521-0391.2010.00076.x
   PubMed Web of Science ®Google Scholar
• Mason BJ, Crean R, Goodell V, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology. 2012;37(7):1689–1698. doi:10.1038/npp.2012.14
   PubMed Web of Science ®Google Scholar
• Werneck MA, Kortas GT, de Andrade AG, Castaldelli-Maia JM, de Andrade AG. A systematic review of the efficacy of cannabinoid agonist replacement therapy for cannabis withdrawal symptoms. CNS Drugs. 2018;32(12):1113–1129. doi:10.1007/s40263-018-0577-6
   PubMed Web of Science ®Google Scholar
• Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L. Psychosocial interventions for cannabis use disorder. Cochrane Database Syst Rev. 2016;2016(5):CD005336. doi:10.1002/14651858.CD005336.pub4
   PubMedGoogle Scholar
• Maree RD, Marcum ZA, Saghafi E, Weiner DK, Karp JF. A systematic review of opioid and benzodiazepine misuse in older adults. Am J Geriatr Psychiatry. 2016;24(11):949–963. doi:10.1016/j.jagp.2016.06.003
   PubMed Web of Science ®Google Scholar
• Ates Bulut E, Isik AT. Abuse/Misuse of prescription medications in older adults. Clin Geriatr Med. 2022;38(1):85–97. doi:10.1016/j.cger.2021.07.004
   PubMed Web of Science ®Google Scholar
• Wang YP, Andrade LH. Epidemiology of alcohol and drug use in the elderly. Curr Opin Psychiatry. 2013;26(4):343–348. doi:10.1097/YCO.0b013e328360eafd
   PubMed Web of Science ®Google Scholar
• Gerlach LB, Wiechers IR, Maust DT. Prescription benzodiazepine use among older adults: a critical review. Harv Rev Psychiatry. 2018;26(5):264–273. doi:10.1097/HRP.0000000000000190
   PubMed Web of Science ®Google Scholar
• Marra EM, Mazer-Amirshahi M, Brooks G, van den Anker J, May L, Pines JM, Ambulatory Clinics and Emergency Departments. Benzodiazepine prescribing in older adults in U.S. J Am Geriatr Soc. 2015;63(10):2074–2081. doi:10.1111/jgs.13666
   PubMed Web of Science ®Google Scholar
• Schepis TS, Teter CJ, Simoni-Wastila L, McCabe SE. Prescription tranquilizer/sedative misuse prevalence and correlates across age cohorts in the US. Addict Behav. 2018;87:24–32. doi:10.1016/j.addbeh.2018.06.013
   PubMed Web of Science ®Google Scholar
• Schepis TS, Wastila L, McCabe SE. Prescription tranquilizer/sedative misuse motives across the US population. J Addict Med. 2021;15(3):191–200. doi:10.1097/ADM.0000000000000736
   PubMed Web of Science ®Google Scholar
• Santos-Pérez MI, Fierro I, Salgueiro-Vázquez ME, Sáinz-Gil M, Martín-Arias LH. A cross-sectional study of psychotropic drug use in the elderly: consuming patterns, risk factors and potentially inappropriate use. Eur J Hosp Pharm. 2021;28(2):88–93. doi:10.1136/ejhpharm-2019-001927
   PubMedGoogle Scholar
• Freyche C, Zacarin A, Bagheri H. Potentially inappropriate psychotropic drug prescription in elderly people in West Occitanie area. Therapie. 2022;77(5):541–548. doi:10.1016/j.therap.2021.12.018
   PubMed Web of Science ®Google Scholar
• Azab M, Novella A, Ianes A, Pasina L. Potentially inappropriate psychotropic drugs in nursing homes: an Italian Observational Study. Drugs Aging. 2024;41(2):187–197. doi:10.1007/s40266-023-01083-9
   PubMed Web of Science ®Google Scholar
• Weaver MF. Prescription Sedative Misuse and Abuse. Yale J Biol Med. 2015;88(3):247–256.
   PubMedGoogle Scholar
• Paterniti S, Dufouil C, Alpérovitch A. Long-term benzodiazepine use and cognitive decline in the elderly: the epidemiology of vascular aging study. J Clin Psychopharmacol. 2002;22(3):285–293. doi:10.1097/00004714-200206000-00009
   PubMed Web of Science ®Google Scholar
• Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons [published correction appears in. Arch Intern Med. 2009;169(21):1952–1960. doi:10.1001/archinternmed.2009.357
   PubMedGoogle Scholar
• Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J. Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of Hip fracture. Am J Psychiatry. 2001;158(6):892–898. doi:10.1176/appi.ajp.158.6.892
   PubMed Web of Science ®Google Scholar
• Dassanayake T, Michie P, Carter G, Jones A. Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence. Drug Saf. 2011;34(2):125–156. doi:10.2165/11539050-000000000-00000
   PubMed Web of Science ®Google Scholar
• Darker CD, Sweeney BP, Barry JM, Farrell MF, Donnelly-Swift E. Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. Cochrane Database Syst Rev. 2015;2015(5):CD009652. doi:10.1002/14651858.CD009652.pub2
   PubMedGoogle Scholar
• Williams S, Miller G, Khoury R, Grossberg GT. Rational deprescribing in the elderly. Ann Clin Psychiatry. 2019;31(2):144–152.
   PubMed Web of Science ®Google Scholar
• Soyka M. Treatment of benzodiazepine dependence. N Engl J Med. 2017;376(12):1147–1157. doi:10.1056/NEJMra1611832
   PubMed Web of Science ®Google Scholar
• Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs. 2009;23(1):19–34. doi:10.2165/0023210-200923010-00002
   PubMed Web of Science ®Google Scholar
• Shastay A. Opioid Abuse in Older Adults. Home Healthc Now. 2020;38(6):336–337. doi:10.1097/NHH.0000000000000930
   PubMedGoogle Scholar
• Konakanchi JS, Sethi R. The growing epidemic of opioid use disorder in the elderly and its treatment: a review of the literature. Prim Care Comp CNS Dis. 2023;25(1):21r03223. doi:10.4088/PCC.21r03223
   PubMedGoogle Scholar
• Han B, Polydorou S, Ferris R, Blaum CS, Ross S, McNeely J. Demographic trends of adults in new york city opioid treatment programs--an aging population. Subst Use Misuse. 2015;50(13):1660–1667. doi:10.3109/10826084.2015.1027929
   PubMed Web of Science ®Google Scholar
• Substance Abuse Mental Health Services Administration (SAMHSA). TIP 63: medications for opioid use disorder: for healthcare and addiction professionals, policymakers, parents, and families. Available from: https://store.samhsa.gov/sites/default/files/pep21-02-01-002.pdf. Accessed july 9 2024.
   Google Scholar
• Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths - United States, 2013-2017. MMWR Morb Mortal Wkly Rep. 2018;67(5152):1419–1427. doi:10.15585/mmwr.mm675152e1
   PubMedGoogle Scholar
• Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder [published correction appears in. JAMA Network Open. 2020;3(2):e1920622. doi:10.1001/jamanetworkopen.2019.20622
   PubMed Web of Science ®Google Scholar
• Rieb LM, Samaan Z, Furlan AD, et al. Canadian guidelines on opioid use disorder among older adults. Can Geriatr J. 2020;23(1):123–134. doi:10.5770/cgj.23.420
   PubMed Web of Science ®Google Scholar
• Chase C. National practice guideline for the use of medications in the treatment of addiction involving opioid use. American Soc Add Med. 2015;1:1.
   Google Scholar
• Carew AM, Comiskey C. Treatment for opioid use and outcomes in older adults: a systematic literature review. Drug Alcohol Depend. 2018;182:48–57. doi:10.1016/j.drugalcdep.2017.10.007
   PubMed Web of Science ®Google Scholar
• Ling W, Nadipelli VR, Solem CT, et al. Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: a long-term study. J Subst Abuse Treat. 2020;110:1–8. doi:10.1016/j.jsat.2019.11.004
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict. 2010;19(1):4–16. doi:10.1111/j.1521-0391.2009.00005.x
   PubMed Web of Science ®Google Scholar
• Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: World Health Organization; 2009. Annex 12, Prescribing guidelines. Available from: https://www.ncbi.nlm.nih.gov/books/NBK143167/. Accessed july 9, 2024.
   Google Scholar
• Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: a clinical practice guideline from the American pain society and college on problems of drug dependence, in collaboration with the heart rhythm society. J Pain. 2014;15(4):321–337. doi:10.1016/j.jpain.2014.01.494
   PubMed Web of Science ®Google Scholar
• Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. doi:10.1136/bmj.j1550
   PubMed Web of Science ®Google Scholar
• Sullivan MA, Garawi F, Bisaga A, et al. Management of relapse in naltrexone maintenance for heroin dependence. Drug Alcohol Depend. 2007;91(2–3):289–292. doi:10.1016/j.drugalcdep.2007.06.013
   PubMed Web of Science ®Google Scholar
• Tanum L, Solli KK, Latif ZE, et al. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial [published correction appears in JAMA Psychiatry. JAMA Psychiatry. 2017;74(12):1197–1205. doi:10.1001/jamapsychiatry.2017.3206
   PubMed Web of Science ®Google Scholar
• Lee JD, Ev N, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomized controlled trial. Lancet. 2018;391(10118):309–318. doi:10.1016/S0140-6736(17)32812-X
   PubMed Web of Science ®Google Scholar
• Loreck D, Brandt NJ, DiPaula B. Managing Opioid Abuse in Older Adults: clinical Considerations and Challenges. J Gerontol Nurs. 2016;42(4):10–15. doi:10.3928/00989134-20160314-04
   PubMed Web of Science ®Google Scholar
• Rivers E, Shirazi E, Aurora T, et al. Cocaine use in elder patients presenting to an inner-city emergency department. Acad Emerg Med. 2004;11(8):874–877. doi:10.1111/j.1553-2712.2004.tb00771.x
   PubMed Web of Science ®Google Scholar
• Ghantous Z, Ahmad V, Khoury R. Illicit drug use in older adults: an invisible epidemic? Clin Geriatr Med. 2022;38(1):39–53. doi:10.1016/j.cger.2021.07.002
   PubMed Web of Science ®Google Scholar
• Redden WM, Paracha SU, Sheheryar Q. Hallucinogen use and misuse in older adults. Clin Geriatr Med. 2022;38(1):55–66. doi:10.1016/j.cger.2021.07.007
   PubMed Web of Science ®Google Scholar